Silodosin Capsule
Product Images NDC 62332-405

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Silodosin (NDC 62332-405). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Alembic Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

30 Capsues In 1 Bottle (Silodosin 4mg)

This is a description of a prescription drug called Silodosin, which comes in a capsule form with 4mg of dosage. Each capsule is to be orally taken once daily with a meal. It is manufactured by Alembic Pharmaceuticals Limited in Gujarat, India, and distributed by Alembic Pharmaceuticals, Inc. in the USA. The capsules should be stored at 25°C (77°F), and protected from light and moisture. The package insert provides prescribing information, and it has a GTIN code of 00362332405305.*

FDA Label Image

30 Capsules (Silodosin 8mg)

FDA Label Image

Figure 1 (Silodosin Figur1)

FDA Label Image

Figure 2 (Silodosin Figur2)

The text describes a study analyzing the change from baseline (pre-treatment) in IPSS total score. The results indicate statistical significance (p<0.0001) and involve variables such as Aries Placebo and Silodosin Capsules 8 mg. However, without more context, it is unclear what the IPSS total score represents or the purpose of the study.*

FDA Label Image

Figure 3 (Silodosin Figur3)

The text is reporting data on the change from baseline in IPSS total score for a clinical trial with a placebo group and a group that received Silodosin Capsules 8 mg. The notation ** p<0.0001 suggests that there was a statistically significant difference between the two groups. The data is shown graphically in a table indicating the score for each group at Day 28 and Day 84/LOCF.*

FDA Label Image

Figure 4 (Silodosin Figur4)

The text represents a table showing changes in maximum flow rate (Qmax) for a medication called Silodosin Capsules 8 mg compared to a placebo. The asterisk denotes a statistically significant difference (p<0.05) from the placebo group. The values in the table represent the change from baseline Qmax in mL/sec. The last row shows the day of measurement.*

FDA Label Image

Figure 5 (Silodosin Figur5)

The text describes a graph or chart displaying changes from a baseline in Qmax (maximum urine flow rate in mL per second) over time (in days). The data includes two sets of values, one for a placebo group and one for a group taking Silodosin Capsules 8 mg. The asterisk and "p<0.05" indicate a statistically significant difference between the two groups at some point in time (not specified). The legend provides information about the time intervals measured (-1 to 84 days) and the method of analysis used (last observation carried forward, or LOCF).*

FDA Label Image

Structure (Silodosin Structure)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.